Q2 EPS Forecast for PROCEPT BioRobotics Boosted by Analyst

PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report) - Equities researchers at Leerink Partnrs boosted their Q2 2025 earnings estimates for shares of PROCEPT BioRobotics in a research report issued on Monday, July 14th. Leerink Partnrs analyst M. Kratky now expects that the company will earn ($0.42) per share for the quarter, up from their prior estimate of ($0.43). The consensus estimate for PROCEPT BioRobotics' current full-year earnings is ($1.75) per share. Leerink Partnrs also issued estimates for PROCEPT BioRobotics' FY2025 earnings at ($1.53) EPS, FY2026 earnings at ($1.15) EPS and FY2028 earnings at ($0.22) EPS.

A number of other equities analysts have also recently weighed in on the stock. Stephens started coverage on shares of PROCEPT BioRobotics in a research report on Wednesday, July 9th. They issued an "overweight" rating and a $70.00 price objective for the company. Morgan Stanley decreased their price objective on shares of PROCEPT BioRobotics from $71.00 to $68.00 and set an "overweight" rating for the company in a research report on Tuesday. Bank of America decreased their price objective on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating for the company in a research report on Friday, April 25th. Truist Financial decreased their price objective on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a research report on Friday, April 11th. Finally, Wall Street Zen cut shares of PROCEPT BioRobotics from a "hold" rating to a "sell" rating in a research report on Saturday, July 12th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $84.13.

PROCEPT BioRobotics Stock Down 1.0%

PROCEPT BioRobotics stock traded down $0.58 during trading on Wednesday, reaching $58.35. 1,834,155 shares of the company's stock were exchanged, compared to its average volume of 854,800. The company's 50-day moving average is $58.73 and its two-hundred day moving average is $62.06. The company has a debt-to-equity ratio of 0.13, a quick ratio of 7.75 and a current ratio of 8.95. PROCEPT BioRobotics has a 52-week low of $47.04 and a 52-week high of $103.81. The firm has a market cap of $3.23 billion, a price-to-earnings ratio of -34.32 and a beta of 1.07.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.04. PROCEPT BioRobotics had a negative net margin of 36.20% and a negative return on equity of 28.09%. The firm had revenue of $69.16 million during the quarter, compared to analysts' expectations of $65.39 million. During the same period in the prior year, the company earned ($0.51) EPS. The firm's revenue was up 55.5% on a year-over-year basis.

Insider Activity

In other news, Director Antal Rohit Desai sold 25,000 shares of the company's stock in a transaction dated Thursday, June 12th. The shares were sold at an average price of $61.49, for a total value of $1,537,250.00. Following the sale, the director owned 14,363 shares in the company, valued at approximately $883,180.87. This represents a 63.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders have sold 100,000 shares of company stock valued at $6,271,250. Corporate insiders own 6.60% of the company's stock.

Institutional Investors Weigh In On PROCEPT BioRobotics

A number of institutional investors have recently modified their holdings of PRCT. FMR LLC raised its stake in PROCEPT BioRobotics by 11.9% during the fourth quarter. FMR LLC now owns 8,159,208 shares of the company's stock worth $656,979,000 after acquiring an additional 866,328 shares during the period. Vanguard Group Inc. raised its stake in PROCEPT BioRobotics by 6.1% during the fourth quarter. Vanguard Group Inc. now owns 5,140,426 shares of the company's stock worth $413,907,000 after acquiring an additional 297,075 shares during the period. Alliancebernstein L.P. raised its stake in PROCEPT BioRobotics by 22.3% during the first quarter. Alliancebernstein L.P. now owns 2,143,693 shares of the company's stock worth $124,892,000 after acquiring an additional 391,215 shares during the period. Wellington Management Group LLP raised its stake in PROCEPT BioRobotics by 38.8% during the fourth quarter. Wellington Management Group LLP now owns 1,490,952 shares of the company's stock worth $120,051,000 after acquiring an additional 416,819 shares during the period. Finally, T. Rowe Price Investment Management Inc. raised its stake in PROCEPT BioRobotics by 43.6% during the first quarter. T. Rowe Price Investment Management Inc. now owns 1,415,403 shares of the company's stock worth $82,462,000 after acquiring an additional 429,461 shares during the period. Institutional investors and hedge funds own 89.46% of the company's stock.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).